Overview
Ibogaine is a psychoactive indole alkaloid found in the root bark of Tabernanthe iboga, a shrub native to Central Africa. It is best documented as an experimental interruption of opioid withdrawal and craving, and has more recently been studied in people with a history of head injury[11][1]. Pages and providers that address lacrosse players apply that general material to a specific athletic population[12][13].
There is, at the time of writing, no published trial, case series or registry study of ibogaine in lacrosse athletes. Any claim of a lacrosse-specific outcome should be treated as unsupported. What exists is evidence about head impacts in contact sports on one side, and early evidence about ibogaine in other head-injured populations on the other[4][5][1].
Why lacrosse is discussed
Lacrosse is a stick-and-contact sport with documented concussion and catastrophic-injury surveillance. A four-decade surveillance review of youth, high-school and collegiate lacrosse recorded catastrophic injuries and exertional medical events across the sport[6], and a bibliometric review found that the most-cited lacrosse research is dominated by concussion and traumatic brain injury[7]. That literature explains the interest; it does not evaluate ibogaine.
Provider-facing material aimed at lacrosse players generally describes the same program structure offered to other athletes and to veterans: screening, a supervised dosing day, and several days of observation and integration[12][13][14]. Related pages on this site cover concussions, hockey players and rugby players.
Head impacts and CTE evidence in contact sports
Chronic traumatic encephalopathy (CTE) is a neurodegenerative tauopathy described in people with a history of repetitive head impacts. A neuropathological series in Brain set out a staged spectrum of the disease across contact-sport athletes and other exposed groups[4], and a later brain-bank analysis published in JAMA reported CTE in a large majority of donated brains from former American football players — a convenience sample that cannot be read as a population prevalence[5].
CTE can currently only be diagnosed after death. No treatment, ibogaine included, has been shown to prevent, halt or reverse it. Persistent symptoms after concussion — headache, sleep disruption, irritability, attention and mood problems — are what living athletes actually present with, and these are the symptoms that ibogaine research in head-injured groups has measured[1].
Ibogaine and brain-injury research
The most-cited human evidence is a 2024 Nature Medicine open-label study, conducted with Stanford investigators, of magnesium–ibogaine in 30 US special-operations veterans with traumatic brain injury. Participants showed improvements in disability, post-traumatic stress, depression and anxiety measures at one month, with no serious cardiac events reported under monitoring[1][2]. The design had no control group and no randomization, so expectation effects and selection cannot be separated from drug effects.
An earlier retrospective survey of special-operations veterans who had traveled abroad for ibogaine and 5-MeO-DMT reported reductions in self-rated trauma symptoms and cognitive complaints, again without controls[3]. Mechanistic discussion usually centers on neuroplasticity and on the long-lived metabolite noribogaine rather than on any repair of tau pathology; see noribogaine and neuroplasticity and traumatic brain injury. Descriptions of how the experience itself is reported by participants can be found in provider material[16].
Substance use and pain after a sports career
Some athletes seek ibogaine for opioid or alcohol dependence rather than for head injury. Here the observational evidence is larger, though still uncontrolled: a twelve-month follow-up study of people treated for opioid dependence reported sustained reductions in use for a subset of participants[10], and a review of the field describes both the reported benefits and the practical dangers of treatment outside regulated medicine[9].
Risks and cardiac safety
Ibogaine blocks the hERG potassium channel and prolongs the QT interval, which can lead to torsades de pointes and cardiac arrest; the pharmacological basis of this effect is well described[8]. A systematic review of adverse events in humans catalogs cardiac, neurological and gastrointestinal effects, including deaths reported in unmonitored settings[9]. Screening usually includes an electrocardiogram, electrolyte correction (magnesium and potassium), liver function testing and a review of interacting medications, with continuous cardiac monitoring during dosing[1][11]. Athletes taking stimulants, antidepressants or opioid agonists face additional interaction risk. Fuller detail is on the cardiac risk page.
Settings, access and cost
Ibogaine is a Schedule I substance in the United States, so athletes who pursue treatment generally travel to jurisdictions where it is unscheduled, most commonly Mexico and Costa Rica[11]. Provider material describes multi-day residential programs with medical screening, a single flood dose and integration support[12][13][15]. Published prices vary widely and are not covered by insurance because the treatment is unapproved; see ibogaine treatment cost and ibogaine legality.
What is not known
- No randomized controlled trial of ibogaine for brain injury of any kind has be